Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release,
“The surge in demand for alternative options to traditional mental health support have fueled interest and curiosity in the burgeoning field of psychedelic-assisted therapy. Mounting evidence suggests that when used in conjunction with therapeutic and medical protocols, psychedelics have the potential to bring relief to those whose conditions have been resistant to traditional approaches.”
That’s opening doors for companies such as NeonMind Biosciences (CSE: NEON) (OTC: NMDBF), Cybin Inc. (NEO: CYBN) (OTC: CLXPF), Field Trip Health Ltd. (TSX: FTRP) (NASDAQ: FTRP), Mind Cure Health Inc. (CSE: MCUR) (OTC: MCURF), and ATAI Life Sciences (NASDAQ: ATAI).
In addition, according to Mad in America, “In an interview published in Nature, psychopharmacologist and psychedelic researcher, David Nutt, suggests that psychedelics ‘turn off parts of the brain that relate to depression’ and ‘reset the brain’s thinking processes’ via their actions on cortical 5-HT2A receptors. Others assert they enhance brain ‘connectivity.’” With more studies pointing to positive solutions for mental health issues, it may only be a matter of time before the psychedelics boom really takes off.